Qiagen price target lowered to $50 from $55 at BofA

BofA lowered the firm’s price target on Qiagen (QGEN) to $50 from $55 and keeps a Buy rating on the shares. Sentiment for Life Sciences and Diagnostic Tools and Contract Research Organizations is “particularly negative” heading into earnings given that these companies “sit at the intersection of a number of policy changes from the Trump Administration,” including headwinds from NIH budget cuts and global tariffs, as well as broader macro concerns, especially around China, the analyst tells investors in a preview for the group.